Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs has exercised its put option rights, resulting in a Share-for-Share Exchange where Psyence will issue 1,146,159 common shares valued at $5 million to acquire 2,900 PsyLabs shares. Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed. The deal is expected to...

Psyence BioMed's board has ratified a put option agreement with PsyLabs, a leading pharmaceutical-grade psychedelic manufacturer. The agreement grants PsyLabs the right to require Psyence to make further equity investments while securing reliable supply of pharmaceutical-grade psychedelics for clinical and commercial programs. The structure prese...

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its 1-for-6.25 reverse stock split will become effective on February 2, 2026, after being delayed from its original January 20 date. The consolidation will reduce outstanding shares from 6,388,604 to 1,022,177. The company's shares will continue trading under the symbol 'PBM' with a new CUSIP n...

Psyence Biomedical Ltd. (Nasdaq: PBM) announced the adjournment of its annual and special shareholder meeting originally scheduled for January 22, 2026, to February 12, 2026, due to failure to achieve the requisite quorum. The company is working with proxy agents to ensure sufficient shareholder participation at the rescheduled meeting.

Psyence BioMed advanced its Phase IIb clinical trial for psilocybin-assisted psychotherapy in palliative care, secured nature-derived psilocybin and ibogaine supply, and positioned itself as a leader in longevity science research.